Latest Breaking News On - Biocon biologics ltd - Page 5 : comparemela.com

Biocon Biologics, Sandoz sign pact to distribute adalimumab biosimilar Humira in Japan

Adalimumab BS for subcutaneous injection is a biosimilar of Humira, offering therapeutic solutions for immune-related diseases such as rheumatoid arthritis, psoriasis vulgaris, ankylosing spondylitis, Crohn s disease and ulcerative colitis

Biocon Biologics partners with Sandoz for distribution of its biosimilar to treat immune-related diseases in Japan

Biocon Biologics Partners with Sandoz for the Distribution of "Adalimumab BS Subcutaneous Injection [FKB]" in Japan – India Education | Latest Education News | Global Educational News

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), signed today a Distribution Agreement with Sandoz,  granting the Company the exclusive rights to promote, sell and

Biocon Biologics Concludes Integration of Acquired Biosimilars Business in ~120 countries

Biocon Biologics, a unique, fully integrated, global biosimilars company with a rich portfolio of insulins and monoclonal antibodies, has successfully concluded the integration of the acquired Viatris biosimilars business with the transition of 10+ Emerging Markets and Japan, Australia and New Zealand in the final phase.

CNBC-TV18 recognises excellence in Business & Leadership at India Business Leader Awards 2023